Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
| ▸ | CCNH | P51946 | 1/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28572246 | 0.95 | L3MBTL1 (0.62) | L3MBTL1TSHRLMNAHTTSMN1; SMN2 | |
| SCHEMBL3701951 | 0.88 | CA12 (0.71) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23057261 | 0.85 | IDO1 (0.72) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14838614 | 0.85 | FFAR4 (0.70) | L3MBTL1TSHRLMNAMEN1KMT2A | |
| SCHEMBL259382 | 0.85 | CA12 (0.66) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL31681311 | 0.85 | CA12 (0.66) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL28560165 | 0.84 | CA12 (0.65) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL26463794 | 0.84 | CYP19A1 (0.78) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1592806 | 0.84 | LMNA (0.60) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2240551 | 0.84 | HTR6 (0.73) | LMNAHTTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275539-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | L3MBTL1 4054/4885TSHR 573/4885LMNA 4109/4885 |
| US-20250275539-A1 | APYRASE INHIBITORS | APEH, GBA3, PON1 | L3MBTL1 369/4885TSHR 2783/4885LMNA 3363/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | L3MBTL1 2848/4885TSHR 2394/4885LMNA 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.